Prevalence of Glucose Intolerance and New- Onset Diabetes in COVID-19 Infected Patients in Babylon Province, Iraq

Iman Shaker Abd Al-Zahra; Nihad Abdallah  Selman

Iman Shaker Abd Al-Zahra Babylon Health Director, Babylon, Iraq.
Nihad Abdallah Selman Assistant Professor, College of Medicine, University of Babylon, Endocrinologist.

Keywords: Prevalence, Glucose Intolerance, New-onset Diabetes, Babylon Province

Abstract

Background: The pathology of COVID-19 was found to go beyond acute respiratory infection. Hyper-inflammatory syndrome had described among some patients. Many persons with COVID-19 who require hospitalization also have diabetes, according to studies.

Objectives: To identify the prevalence of glucose intolerance and newly diagnosed diabetes in COVID-19 infected patients and its correlation with disease severity and drugs used.

Methodology: A cross-sectional study was conducted in Marjan Medical City during April-July 2021. The study included 355 patients not previously diagnosed with diabetes who were admitted to the hospital for COVID-19 infection.

Results: Mean age of participants was (48.12 Â± 15.51) years, with females constituting the larger proportion (53.52%). Newly diagnosed diabetic patients formed (15.77%) while pre-diabetic patients formed (22.82%). The use of certain medications was found to be significantly related to diabetes status, including Favipiravir and Remdesivir. Lung involvement was found to be significantly higher among diabetic (42.3% Â± 17.2%) and pre-diabetics (40.1% Â± 13.0%) compared to non-diabetics (35.0% Â± 14.8%).

Conclusion: Approximately (39%) of the patients with COVID-19 in various age groups had pre-diabetes status or newly diagnosed diabetes that was not diagnosed. Those patients had a significantly higher level of lung involvement compared to non-diabetic patients.

How to cite this article:
Abd Al-Zahra IS, Selman NA. Prevalence of Glucose Intolerance and New-Onset Diabetes in COVID-19 Infected Patients in Babylon Province, Iraq. Special Issue - COVID-19 & Other Communicable Disease. 2022;150-156.

DOI: https://doi.org/10.24321/0019.5138.202224

References

Rajpal A, Rahimi L, Ismail-Beigi F. Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes. J Diabetes. 2020 Dec;12(12):895-908. [PubMed] [Google Scholar]

Vechorko V, Evsikpv E, Baykova O, Teplova N, Doroshenko D. Frequency of hyperglycemia in patients with Covid-19 infection and pneumonia. In: Biotechnology to combat COVID-19. IntechOpen; 2021, p. 1-18. [Google Scholar]

Lohmann T, Wagner M. Hyperglycemia associated with hospitalization for severe COVID-19 infection. MLO Continuing Education. 2020, p. 1-16.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar;395(10229):1054-62. [PubMed] [Google Scholar]

Coppelli A, Giannarelli R, Aragona M, Penno G, Falcone M, Tiseo G, Ghiadoni L, Barbieri G, Monzani F, Virdis A, Menichetti F, Del Prato S; Pisa COVID-19 Study Group. Hyperglycemia at hospital admission is associated with severity of the prognosis in patients hospitalized for COVID-19: The Pisa COVID-19 study. Diabetes Care. 2020 Oct;43(10):2345-8. [PubMed] [Google Scholar]

Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, Mingrone G, Boehm B, Cooper ME, Chai Z, Del Prato S, Ji L, Hopkins D, Herman WH, Khunti K, Mbanya JC, Renard E. New-Onset diabetes in Covid-19. N Engl J Med. 2020 Aug;383(8):789-90. [PubMed] [Google Scholar]

Chobot A, Gorowska-Kowolik K, Sokolowska M, Jarosz-Chobot P. Obesity and diabetes - not only a simple link between two epidemics. Diabetes Metab Res Rev. 2018 Oct;34(7):e3042. [PubMed] [Google Scholar]

Pengpid S, Peltzer K. Overweight and obesity among adults in Iraq: prevalence and correlates from a national survey in 2015. Int J Environ Res Public Health. 2021 Apr;18(8):4198. [PubMed] [Google Scholar]

Shabu S. Prevalence of overweight/obesity and associated factors in adults in Erbil, Iraq: A household survey. Zanco J Med Sci. 2019;23(1):128-34. [Google Scholar]

Vargas-VÃ¡zquez A, Bello-Chavolla OY, Ortiz-Brizuela E, Campos-MuÃ±oz A, Mehta R, Villanueva-Reza M, Bahena-LÃ³pez JP, Antonio-Villa NE, GonzÃ¡lez-Lara MF, Ponce de LeÃ³n A, Sifuentes-Osornio J, Aguilar-Salinas CA. Impact of undiagnosed type 2 diabetes and pre-diabetes on severity and mortality for SARS-CoV-2 infection. BMJ Open Diabetes Res Care. 2021 Feb;9(1):e002026. [PubMed] [Google Scholar]

Li H, Tian S, Chen T, Cui Z, Shi N, Zhong X, Qiu K, Zhang J, Zeng T, Chen L, Zheng J. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes Obes Metab. 2020 Oct;22(10):1897-906. [PubMed] [Google Scholar]

Tee LY, Alhamid SM, Tan JL, Oo TD, Chien J, Galinato P, Tan SY, Humaira S, Fong RKC, Puar TH, Loh WJ, Santosa A, Khoo J, Rosario BH. COVID-19 and undiagnosed pre-diabetes or diabetes mellitus among international migrant workers in Singapore. Front Public Health. 2020 Nov;8:584249. [PubMed] [Google Scholar]

Sathish T, Kapoor N, Cao Y, Tapp R, Zimmet P. Proportion of newly diagnosed diabetes in COVID-19 patients: a systematic review and meta-analysis. Diabetes Obes Metab. 2021 Mar;23(3):870-4. [PubMed] [Google Scholar]

Chee Y, Ng S, Yeoh E. Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus. Diabetes Res Clin Pract. 2020 Jun;164:108166. [PubMed] [Google Scholar]

Ren H, Yang Y, Wang F, Yan Y, Shi X, Dong K, Yu X, Zhang S. Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19. Cardiovascular Diabetology. 2020 May;19(1):58. [PubMed] [Google Scholar]

Smith SM, Boppana A, Traupman JA, Unson E, Maddock DA, Chao K, Dobesh DP, Brufsky A, Connor RI. Impaired glucose metabolism in patients with diabetes, prediabetes and obesity is associated with severe Covidâ€19. J Med Virol. 2021 Jan;93(1):409-15. [PubMed] [Google Scholar]

Sosibo A, Khathi A. Pre-diabetes and COVID-19, could we be missing the silent killer? Exp Biol Med (Maywood). 2021 Feb;246(4):369-70. [PubMed] [Google Scholar]

Mzimela C, Ngubane P, Khathi A. The changes in immune cell concentration during the progression of pre-diabetes to type 2 diabetes in a high-fat high-carbohydrate diet-induced pre-diabetic rat model. Autoimmunity. 2019 Feb;52(1):27-36. [PubMed] [Google Scholar]

Qureshi Q, Ashraf T, Rehman K, Khosa M, Akash M. Therapeutic interventions of remdesivir in diabetic and nondiabetic COVID-19 patients: a prospective observational study conducted on Pakistani population. J Med Virol. 2021 Dec;93(12):6732-6. [PubMed] [Google Scholar]

Oliveira TL, Melo IS, Cardoso-Sousa L, Santos IA, El Zoghbi MB, Shimoura CG, Georjutti RP, Castro OW, Goulart LR, Jardim ACG, Cunha TM, Sabino-Silva R. Pathophysiology of SARS-CoV-2 in Lung of Diabetic Patients. Front Physiol. 2020 Dec;11:587013. [PubMed] [Google Scholar]